PT-141, or bremelanotide, is described as a melanocortin receptor agonist studied in sexual-desire signalling. United States labelling for the approved formulation is narrow: acquired, generalized hypoactive sexual desire disorder in premenopausal women, with stated exclusions — and it notes the mechanism for that indication is not fully known.[1]
Mechanism, stated honestly
The compound acts at melanocortin receptors. Labelling does not present a fully established pathway for the treated condition, so descriptions claiming a precise, proven mechanism go beyond the source.[1]
What the approved indication covers
The approved United States indication is specific to acquired, generalized hypoactive sexual desire disorder in premenopausal women, with exclusions stated in the label. It is not indicated for men, not for postmenopausal women, and not for performance enhancement.[1]
Balanced safety context
The label describes transient increases in blood pressure, nausea, and hyperpigmentation among relevant considerations. A summary that omits these is incomplete rather than concise.[1]
| Approved product | A specific United States formulation with a defined indication and labelling. |
| Research material | Laboratory-use material; not the approved product and not authorized as a medicine. |
| Canadian status | Not asserted here; verify in the Health Canada Drug Product Database. |
Reading checklist
- Quote the indication in full, including its population limits.
- Include blood-pressure, nausea and pigmentation considerations in any summary.
- Do not extend a labelled indication to other populations or to enhancement.
- Keep approved-product facts separate from research-material facts.
An ingredient name is not a finished, approved formulation
Short answer: an ingredient name and an approved branded medicine are different things. Approved labelling describes a specific formulation — a defined strength, presentation, manufacturing process and authorised use. A research-listing name that matches the ingredient does not inherit any of that.
| Approved product | A named formulation assessed by a regulator, with labelling that states strength, presentation and authorised use. |
| Ingredient-name match | Only that a name matches. It carries no assessment, no formulation equivalence and no authorisation. |
| What labelling can be used for | Understanding how the described mechanism and endpoints were characterised for that approved product. |
| What it cannot be used for | Treating a research listing as equivalent, assessed, or authorised. |
This is the same reasoning that applies to searching a regulator's product database: finding an ingredient name there tells you an authorised product exists containing that ingredient. It says nothing about unrelated research material bearing the same name.[1][2]
Questions & answers
Is PT-141 approved for men?
The United States approved indication covers acquired, generalized hypoactive sexual desire disorder in premenopausal women, with exclusions. It is not indicated for men.
Is its mechanism fully understood?
Labelling describes melanocortin receptor agonism but states that the mechanism for the labelled indication is not fully known.
Does US labelling mean it is authorized in Canada?
No. Canadian authorization is a separate question to check in Health Canada’s Drug Product Database.
References
- Official United States prescribing information for bremelanotide injection (Vyleesi), revised March 2024. United States labelling only.
- Health Canada. Drug Product Database: the official list of drug products authorized for sale in Canada.
Owner-provided references describe the studied materials and official guidance, not PEPTIVIA batches, product equivalence, safety or authorization. No independent expert review is claimed.